AI工具脱氧核糖核酸中心通过分析脱氧核糖核酸复制压力,确定癌症治疗对策,为更有效、毒性较低的疗法铺平了道路。 AI tool DNAscent identifies cancer treatment response by analyzing DNA replication stress, paving the way for more effective, less toxic therapies.

昆士兰大学和剑桥大学的研究人员开发了一个名为脱氧核糖核酸中心(DNAcent)的AI平台,该平台分析癌症细胞的DNA复制,以提高化疗效果和减少副作用。 Researchers from the University of Queensland and the University of Cambridge have developed an AI platform called DNAscent that analyzes DNA replication in cancer cells to improve chemotherapy effectiveness and reduce side effects. 通过将AI与DNA测序相结合,该工具检测DNA复制压力——当复制叉子摊位或崩溃时——帮助识别生物标志,以预测个别肿瘤对治疗的反应。 By combining AI with DNA sequencing, the tool detects DNA replication stress—when replication forks stall or collapse—helping identify biomarkers that predict how individual tumors respond to treatment. 这样可以提供更有针对性的治疗,避免健康的细胞,从而有可能减少常见副作用,如发毛和血液紊乱。 This could enable more targeted therapies that spare healthy cells, potentially reducing common side effects like hair loss and blood disorders. 虽然尚未做好临床使用准备,但脱氧核糖核酸的成绩优于以前的方法,也可能适用于其他疾病,包括疟疾。 While not yet ready for clinical use, DNAscent outperforms previous methods and may also apply to other diseases, including malaria. 澳大利亚预计到2025年将新增约170 000例癌症病例,尽管病例数在增加,但在过去30年中存活率有所改善。 In Australia, where about 170,000 new cancer cases are expected in 2025, survival rates have improved over the past 30 years despite rising case numbers.